Mark Vickery

Web Content Editor

312-265-9380

Visit: www.zacks.com

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Everest Re Group, Ltd. (NYSE: RE), State Auto Financial Corp. (Nasdaq: STFC), Sangamo Biosciences, Inc. (Nasdaq: SGMO), Lloyds TSB Group Plc. (NYSE: LYG) and HBOS Plc. (Nasdaq: HBOS).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579

Here are highlights from Friday's Analyst Blog:

Everest Re Peaks at a Hold

Everest Re Group, Ltd. (NYSE: RE) intends to release its 3Q08 earnings later this month. The company continues to experience rate pressures resulting from increased competition, higher commissions, and increased retentions by the ceding companies. Competition continues with a greater intensity in the US than in the international markets.

However, the company's results should be able to benefit from its strong risk-adjusted capitalization, good long-term operating performance, strong traditional risk management capabilities, well- diversified product lines and excellent market profile as a leading global reinsurance franchise, going forward. Even so, our Hold recommendation on the shares remains in place, presently.

State Auto Kept in Neutral

Headquartered in Columbus, Ohio, State Auto Financial Corporation (Nasdaq: STFC) is a property & casualty insurance holding company formed in June 1991 by State Automobile Mutual Insurance Company (Mutual), an Ohio mutual P&C company. Founded in 1921, Mutual currently owns approximately two-thirds of STFC.

STFC is expected to release its 3Q08 results on October 23, 2008. The company reported operating losses of $0.12 per share in 2Q08, versus operating net income of $0.51 per share in the prior year quarter, driven by a record level of catastrophe losses of $76.8 million.

Sangamo Biotech a Strong Buy

Sangamo Biosciences, Inc. (Nasdaq: SGMO) is a biopharmaceutical company engaging in designing and developing engineered transcription factors for gene regulation. The company uses a proprietary gene regulation technology to discover and develop a new class of therapeutic candidates for cardiovascular disease, cancer, neuropathic pain and immune diseases, such as sickle cell anemia and HIV.

Sangamo uses a proprietary ZFP gene regulation technology to discover and develop a new class of therapeutic candidates for diabetic neuropathy, cardiovascular disease, cancer and immune diseases.